Navigation Links
Bionovo Announces First Quarter 2009 Highlights and Financial Results
Date:5/7/2009

EMERYVILLE, Calif., May 7 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced first quarter highlights and financial results for the three months ended March 31, 2009.

Company Highlights

  • Bionovo presented data on a preclinical anti-cancer drug candidate, BN108, at the American Association of Cancer Research (AACR) conference in April. TspA3 has been identified as an active compound of BN108 that is responsible for BN108's selective cytotoxicity. BN108 and TspA3 induce apoptosis through rapid inactivation of AKT and mTOR kinases in breast cancer cells but not in normal cells.
  • Two additional members joined Bionovo's Scientific Advisory Board, Jan-Ake Gustafsson and Bert W. O'Malley.
  • The Company continues to work towards satisfying the FDA's requests for clarification of the manufacturing and analytical strategy to be used in ensuring the consistency of its drug products.
  • The Company continues to pursue a wide variety of funding options including government grants, partnering, and debt and equity offerings.

First Quarter Results

Total operating expenses for the three months ending March 31, 2009 were $4.6 million compared to $4.2 million for the same period in 2008. Total operating expenses for the first quarter included one-time expenses associated with the relocation of the Company's headquarters, the purchase of raw materials for manufacturing purposes throughout the year, and severance costs. The Company expects operating expenses to decrease in the second quarter.

The Company reported a net loss for the three months ended March 31, 2009 of $4.7 million, or $0.06 per share, compared with a net loss of $3.9 million, or $0.05 per share,
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
2. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
3. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
4. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
5. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
8. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
9. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
10. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
11. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  Restore Health, a leading personalized ... announced that it is now offering pharmacogenetics testing ... individual based upon their particular genetic makeup. Comprehensive ... interaction between a patient,s genetics and their entire ... to provide this new service to healthcare providers ...
(Date:7/24/2014)... , Germany , and ... -- , Exclusive global license ... for SF3B1 mutations, including next-generation sequencing (NGS) gene panels, ... to be targeted by new test, indicate favorable prognosis ... syndromes  QIAGEN sees potential for developing companion ...
(Date:7/24/2014)... CITY, Calif., July 24, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis systems, today reported financial results for ... First quarter overview: , Revenues of $47.5 ... , Diluted EPS of $0.21, up 50% over last ... Medical market revenues of $7.2 million, up 20% over ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11
... Intercept Pharmaceuticals, Inc., has announced that its first-in-class farnesoid ... endpoint of improved insulin sensitization in a 6 week ... patients with nonalcoholic fatty liver disease (NAFLD). , By ... that a single oral daily dose of INT-747 statistically ...
... , ST. PAUL, Minn., Oct. 1 Algos Therapeutics ... today announces the selection of Dr. Ganesh Iyer as ... his new responsibilities immediately. , "We were incredibly fortunate ... Dr. Iyer to lead Algos," stated Gary Smaby, Algos ...
Cached Medicine Technology:Intercept Pharmaceuticals' FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease 2Algos Attracts CRO Veteran Dr. Ganesh Iyer as its New CEO 2
(Date:7/26/2014)... can provide much-needed relief from the summer heat, but ... much chlorinated water, experts warn. Amid the splashing ... water in their mouth. Some kids may even take ... parents. Although swallowing a small amount of pool ... that ingesting too much can lead to chlorine poisoning ...
(Date:7/26/2014)... (PRWEB) July 26, 2014 As reported ... on July 23rd, new research by Palo Alto Networks ... rewrite their playbook, now focusing more on businesses and ... who have become increasingly wise to their tactics over ... and CEO/CTO, Joe Caruso, talks about the evolution of ...
(Date:7/26/2014)... Multiple sclerosis (MS), also known as ... disease in which the insulating covers of nerve ... damaged. This damage disrupts the ability of parts ... a wide range of signs and symptoms, including ... takes several forms, with new symptoms either occurring ...
(Date:7/26/2014)... Kentucky (PRWEB) July 26, 2014 ... on the playing field; however, concussions in ... injuries. The occupations with the highest risk of ... ,     Firefighters ,     Police officers , ... workers ,     Delivery personnel , ...
(Date:7/26/2014)... As the category creator and world ... Xoçai is to transform and improve ... chocolate products. One such unique element is XoVita™, ... and blueberries, an ingredient combination exclusive to Xoçai. ... in all of Xoçai products and provides a ...
Breaking Medicine News(10 mins):Health News:Don't Let Kids Drink Pool Water 2Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 2Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 3Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 4Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 5Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 6Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 2Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 3Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 4Health News:KORT Physical Therapists Take the Mystery Out of Identifying and Treating Workplace Head Injuries 2Health News:KORT Physical Therapists Take the Mystery Out of Identifying and Treating Workplace Head Injuries 3Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 2Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 3Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 4
... help because of illnesses related to alcohol abuse seem to ... ,Current official statistics show that emergency wards in ... and emergencies caused due to drunkenness since 1997. ... also have doubled, reported NHS since 1997, accounting for more ...
... up for pricey wine appreciation classes to parse the subtle ... and the black currant// scent of a cabernet sauvignon. Just ... quickly help you become a modest oenophile. It’s up to ... ,A new study by Northwestern University researchers shows that the ...
... official journal of the American Neurological Association, examined brain ... devastated in FTD//. ,Von Economo neurons (VENs) ... evolved in a select group of socially complex species: ... Across species, VENs are localized to frontal brain regions ...
... reach for aspirin. What is giving researchers a headache ... whether there is another form on top of the long-known ... India seems to have solved this controversial puzzle: yes, there ... pure form. ,“The two crystalline forms of ...
... the risk to develop stroke than men, discovered a British study ... of blood to the brain or due to tiny blockages in ... who suffered strokes had 40% more chance to have a family ... chances in those women having mothers who also had a history ...
... finds that 95 percent of Americans have pre marital sex-sex ... American men //and women as far back as the 1940 ... spending hundreds of millions of dollars advising young adults to ... One official disagreed and opined that even if the programs ...
Cached Medicine News:Health News:Researchers Discover How We Differentiate Smells 2Health News:A Study Finds VENs Devastated in FTD 2Health News:Does Aspirin Crystallize? 2
Stainless steel bone clamp....
Reduction Forceps with Points for precise reduction of bone fragments with minimal soft tissue contact....
Designed for proximal femoral elevation in total hip replacement or in other surgery with a similar need for bone manipulation....
Straight double action bone cutting rongeur....
Medicine Products: